The study, published in Lancet Neurology, detailed the “head-to-head” trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which… read more.
A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment… read more.
Type 2 diabetes and prediabetes are associated with accelerated brain ageing, according to a new study from Karolinska Institutet in Sweden published in the journal Diabetes Care. The good news… read more.
UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.
Eisai Co., Ltd. and Biogen Inc. announced that the humanized amyloid-beta (Abeta monoclonal antibody “Leqembi” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the… read more.
Treatment with ubrogepant at the first sign of migraine onset appears to help prevent acute symptoms from developing. Researchers reported their findings on August 28 in Neurology. Author… read more.
Amneal Pharmaceuticals, Inc., announced that the FDA has approved Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). Crexont is a novel, oral formulation… read more.
A new analysis of data from a large study of women’s health shows no link between a history of migraine and the risk of developing Parkinson’s disease (PD)…. read more.
People with multiple sclerosis (MS) do not appear to be at an increased risk of relapse after COVID-19 vaccination, researchers reported on August 14, 2024 in Neurology. “People… read more.
Public health interventions that tackle dementia risk factors could yield as much as £4bn in savings in England by reducing dementia rates and helping people to live longer… read more.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche’s subcutaneous version of Ocrevus (ocrelizumab subcutaneous ) to treat patients with relapsing and primary progressive… read more.
Epidemiologists in Spain have found a new link between childhood sleep patterns and behaviour, with implications for the understanding of attention deficit hyperactivity disorder (ADHD) in preadolescence. The… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
